Genitourinary Clinical Trials
Strategic, Connected Support Across Urology, Nephrology & GU Oncology
Syneos Health delivers integrated genitourinary clinical trials expertise across urology, nephrology and GU oncology, supporting programs in Overactive Bladder (OAB), Lower Urinary Tract Symptoms (LUTS), Benign Prostatic Hyperplasia (BPH), Urinary Tract Infections (UTIs), chronic kidney diseases and prostate, bladder, kidney and testicular cancer clinical trials.
As a leading genitourinary CRO, we help customers proactively identify and mitigate clinical development risks in real time through integrated clinical, medical and commercial expertise, enabling faster development decisions and greater confidence at every stage of the product lifecycle.
Partner with the team built to accelerate your genitourinary development.
Connect with us to explore how our integrated clinical, medical and commercial expertise can help you advance therapies in urology, nephrology and GU oncology with greater clarity, confidence and operational efficiency.
Why Syneos Health for Genitourinary (GU) Clinical Trials
An Extension of Your Team: We work as an extension of your team, bringing together clinical, medical and commercial expertise to align strategy, anticipate challenges and drive informed decisions throughout development. By embedding with your organization and maintaining visibility across functions, we help identify risks early, adapt in real time and advance your program with greater confidence from protocol design through commercialization.
Outcome-Focused Urology Execution: Our urology clinical trials teams focus on eDiary compliance, ePRO/eCOA strategy, endpoint quality and placebo-response mitigation to protect study signal in OAB, LUTS, BPH and IC/BPS programs.
Rare Renal & Transplant Depth: Complex nephrology clinical trials—including CKD, DKD, AKI, rare renal diseases and transplant studies—benefit from integrated planning, site feasibility intelligence and coordinated evidence-generation strategies.
Radiopharma-Ready GU Oncology: We operationalize GU oncology clinical trials across prostate cancer, bladder cancer and renal cell carcinoma, supporting biomarker-driven study design, imaging pathways and radiopharmaceutical oncology trials that align with emerging precision oncology approaches.
What We Deliver
We optimize urology studies through strengthened eDiary compliance, eCOA design, endpoint strategy and site-training practices that reduce variability and improve data quality in OAB, LUTS, BPH, UTI and IC/BPS programs.
Key Urology Indications
- Overactive Bladder (OAB) / Lower Urinary Tract Symptoms (LUTS)
- Benign Prostatic Hyperplasia (BPH/LUTS)
- Urinary Tract Infections (UTIs)
- Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
Our nephrology clinical trial expertise spans CKD, DKD, AKI, rare renal diseases and transplant programs. We design studies around real-world comorbidity patterns, dialysis requirements, transplant-center operations and patient recruitment considerations to support more efficient execution.
Nephrology Focus Areas
- Chronic Kidney Disease (CKD)
- Diabetic Kidney Disease (DKD)
- Acute Kidney Injury (AKI)
- Rare Renal Diseases (IgA nephropathy, FSGS, C3G, Alport syndrome, hyperoxaluria)
- Renal Transplant
We advance GU oncology clinical trials through biomarker-aligned development strategies, operational planning and radiopharmaceutical readiness. Our teams support prostate cancer clinical trials, bladder cancer clinical trials, kidney cancer clinical trials and testicular cancer studies, helping sponsors navigate evolving treatment paradigms across precision oncology and targeted radiotherapy development.
A genitourinary CRO is a contract research organization that specializes in clinical development for conditions affecting the urinary tract, kidneys and male reproductive system. These organizations support study design, site selection, patient recruitment, operational execution, medical oversight and evidence generation across urology, nephrology and GU oncology programs.
Effective execution requires strong eDiary and ePRO/eCOA strategies, robust endpoint planning and comprehensive site and patient training to reduce placebo response, improve compliance and support high-quality outcomes in OAB/LUTS and BPH development programs.
We combine site feasibility intelligence, historical performance data, patient recruitment strategy and technology-enabled outreach to support enrollment acceleration in nephrology and urology studies while maintaining study quality and operational efficiency.
